Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec/liraglutide versus insulin degludec or liraglutide alone in type 2 diabetes
2010-021560-15Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin degludec/liraglutide, Insulin degludec and Liraglutide (3 arms). Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Jan 2011; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021560-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021560-15.